Title |
Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
|
---|---|
Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, March 2017
|
DOI | 10.2147/dmso.s116810 |
Pubmed ID | |
Authors |
Michelle E Orme, Hiep Nguyen, Jackie Y Lu, Susan A Thomas |
Abstract |
Clinical studies of patients with type 2 diabetes show that GLP-1 receptor agonists (GLP-1 RAs) improve glycemic control and promote weight loss. We conducted a Bayesian network meta-analysis (NMA) of placebo- and active-controlled randomized trials to assess the comparative effectiveness of liraglutide, albiglutide, dulaglutide, and exenatide twice daily and once weekly, with a focus on glycemic control. We searched Medline, Embase, and the Cochrane Library (up to December 2014) for core registration programs for US-approved GLP-1 RAs. Patients reaching an A1C target of <7% were analyzed with a binomial model and change in A1C from baseline with a normal model. A covariate analysis assessed the impact of baseline A1C and treatment background on outcomes. The base-case NMA used 23 trials reporting A1C outcomes at ~6 month follow-up. The results, unadjusted and adjusted for baseline A1C, indicated that all GLP-1 RAs resulted in statistically significantly lower A1C at follow-up compared with placebo. The odds of reaching the <7% target were also significantly better compared with placebo. With dulaglutide, exenatide once weekly, and liraglutide, the absolute reduction in A1C at 6 months was 0.9%-1.4%, and was significantly better than exenatide twice daily. Albiglutide was not significantly different from exenatide twice daily. We estimate that ~50% of patients will meet the <7% A1C target within 6 months of commencing GLP-1 RAs. This was a comprehensive assessment of the comparative effectiveness of GLP-1 RAs and A1C outcome. GLP-1 RAs are a viable addition to oral antidiabetes therapy, and dulaglutide, exenatide once weekly, and liraglutide are the most effective. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 44 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 16% |
Student > Ph. D. Student | 6 | 14% |
Student > Master | 5 | 11% |
Student > Bachelor | 3 | 7% |
Other | 3 | 7% |
Other | 8 | 18% |
Unknown | 12 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 30% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
Biochemistry, Genetics and Molecular Biology | 3 | 7% |
Nursing and Health Professions | 3 | 7% |
Environmental Science | 2 | 5% |
Other | 3 | 7% |
Unknown | 16 | 36% |